2018
Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy
Stahl JM, Qian JM, Tien CJ, Carlson DJ, Chen Z, Ratner ES, Park HS, Damast S. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Supportive Care In Cancer 2018, 27: 1425-1433. PMID: 30187220, DOI: 10.1007/s00520-018-4441-5.Peer-Reviewed Original ResearchConceptsVaginal stenosisEndometrial carcinomaMultivariable Cox proportional hazardsMultivariable Cox regression analysisVD useAcademic tertiary referral centerTertiary referral centerCox regression analysisLog-rank testCox proportional hazardsDevelopment of gradeDilator usePelvic radiotherapyReferral centerNoncompliant patientsPrimary outcomeAdjuvant brachytherapyEC patientsConclusionsThe riskRate brachytherapyProportional hazardsOptimal durationPatientsBrachytherapyStudy period
2015
Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation
Rutter CE, Park HS, Corso CD, Yeboa DN, Mancini BR, Lester-Coll NH, Kim AW, Decker RH. Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation. Lung Cancer 2015, 90: 243-248. PMID: 26277031, DOI: 10.1016/j.lungcan.2015.08.002.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerDose-fractionation regimensLimited-stage small cell lung cancerConcurrent CRTConcurrent chemoradiationOverall survivalLimited-stage small-cell lung cancer patientsProportional hazardsSmall cell lung cancer patientsMultivariable Cox proportional hazardsCell lung cancer patientsOptimal radiotherapy doseOngoing randomized trialsInferior overall survivalKaplan-Meier analysisCell lung cancerLarger tumor sizeMedian survival timeLung cancer patientsCox proportional hazardsStandard radiotherapy regimensLarge national datasetChemoradiation regimensSimilar OSEquivalent OSAngiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy
Harder EM, Park HS, Nath SK, Mancini BR, Decker RH. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy. Practical Radiation Oncology 2015, 5: e643-e649. PMID: 26412341, DOI: 10.1016/j.prro.2015.07.003.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyACE inhibitor useNonsteroidal anti-inflammatory drugsAngiotensin receptor blockersRadiation pneumonitisSymptomatic radiation pneumonitisInhibitor useBody radiation therapyAnti-inflammatory drugsRadiation therapyReceptor blockersACE inhibitorsAngiotensin-converting enzyme inhibitor useACE inhibitor usersCommon Terminology CriteriaEnzyme inhibitor usePrimary lung cancerNormal lung tissuesAvailable medical recordsCox proportional hazardsPulmonary doseTerminology CriteriaInhibitor usersAdverse eventsOverall survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply